At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Rimegepant 75 MG [Nurtec]drug
Likely dose
Rimegepant 75 MG [Nurtec]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study
In Brief
A Phase 2 clinical trial evaluating Rimegepant 75 MG [Nurtec] for Irritable Bowel Syndrome. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
202420252026
First PostedJan 2024
Enrollment StartJun 2024
Primary CompletionMay 2025
Study CompletionJun 2025
TodayJul 2026
First PostedJan 24, 2024
Enrollment StartJun 6, 2024
Primary CompletionMay 30, 2025
Study CompletionJun 3, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.4 years ago
Interventions
Rimegepant 75 MG [Nurtec]drug
placebo controlled trial